Skip to main content

Table 2 Comparison of CMR variables between anthracycline and control groups

From: Characterization of subclinical diastolic dysfunction by cardiac magnetic resonance feature-tracking in adult survivors of non-Hodgkin lymphoma treated with anthracyclines

Variable

Anthracycline (n = 18)

Control (n = 17)

p value

LVEF (%)

62.4 ± 7.5

68.0 ± 4.6

0.012

LVEDV (ml)

135.8 ± 31.9

125.5 ± 38.3

0.395

LVESV (ml)

51.2 ± 16.3

40.3 ± 14.9

0.048

LVSV (ml)

84.5 ± 21.3

85.1 ± 25.4

0.932

LVM (g)

118.1 ± 23.6

111.6 ± 25.7

0.444

LVCM (g)

87.9 ± 20.4

83.2 ± 21.1

0.507

LVM/EDV (g/ml)

0.88 ± 0.13

0.92 ± 0.14

0.487

LVEDV index (ml/m2)

73.1 ± 16.1

70.2 ± 17.1

0.612

LVESV index (ml/m2)

27.5 ± 9.4

22.4 ± 7.1

0.085

LVSV index (ml/m2)

45.6 ± 10.7

47.8 ± 11.4

0.567

LVM index (g/m2)

63.7 ± 10.5

62.9 ± 9.9

0.823

LVCM index (g/m2)

47.5 ± 9.1

46.9 ± 8.5

0.841

RVEF (%)

63.7 ± 7.6

67.4 ± 6.8

0.143

RVEDV (ml)

132.3 ± 40.1

127.1 ± 40.5

0.701

RVESV (ml)

48.8 ± 19.8

42.9 ± 19.7

0.382

RVSV (ml)

83.4 ± 24.0

84.1 ± 23.3

0.933

RVEDV index (ml/m2)

70.7 ± 19.8

70.8 ± 18.3

0.994

RVESV index (ml/m2)

26.0 ± 10.5

23.4 ± 9.9

0.450

RVSV index (ml/m2)

44.6 ± 11.3

47.2 ± 10.2

0.479

Native T1 (ms)

1262.8 ± 35.5

1262.7 ± 31.4

0.991

ECV (%)

25.9 ± 0.35

25.6 ± 0.25

0.779

T2 (ms)

40.9 ± 2.4

40.6 ± 1.4

0.672

  1. Data expressed as mean ± standard deviation (SD) or n (%)
  2. LVEF left ventricular ejection fraction, LVEDV left ventricular end-diastolic volume, LVESV left ventricular end-systolic volume, LVSV left ventricular stroke volume, LVM left ventricular mass, LVCM left ventricular cardiomyocyte mass [(1-ECV × LVM], RVEF right ventricular ejection fraction, RVEDV right ventricular end-diastolic volume, RVESV right ventricular end-systolic volume, RVSV right ventricular stroke volume, ECV extracellular volume fraction